PE20110855A1 - Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol - Google Patents

Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol

Info

Publication number
PE20110855A1
PE20110855A1 PE2011000940A PE2011000940A PE20110855A1 PE 20110855 A1 PE20110855 A1 PE 20110855A1 PE 2011000940 A PE2011000940 A PE 2011000940A PE 2011000940 A PE2011000940 A PE 2011000940A PE 20110855 A1 PE20110855 A1 PE 20110855A1
Authority
PE
Peru
Prior art keywords
complex
tramadol
composition
acetaminophen
dosage form
Prior art date
Application number
PE2011000940A
Other languages
English (en)
Inventor
Wei-Guo Dai
Sung Joo Hwang
Jae Hyun Kim
Dong Ho Lee
Liang-Chang Dong
Tae-Hong Choi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41514164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of PE20110855A1 publication Critical patent/PE20110855A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA CAPA DE LIBERACION PROLONGADA (NUCLEO) QUE INCLUYE DESINTEGRANTE TALES COMO CELULOSA EN POLVO, GLICOLATO SODICO DE ALMIDON; ACETAMINOFENO Y TRAMADOL COMPLEJO EN UNA PROPORCION DE 5:1 A 10:1 Y B) UNA CAPA DE COMPOSICION DE LIBERACION INMEDIATA QUE INCLUYE RETARDADOR POLIMERICO HIDROFILICO SELECCIONADO DE AGAR, AGAROSA Y GOMA; ACETAMINOFENO Y TRAMADOL COMPLEJO QUE EN SU MAYOR PARTE NO ESTA EN FORMA DE COMPLEJO; DONDE EL MATERIAL TRAMADOL COMPLEJO ES UN COMPLEJO DE CARRAGENINA LAMBDA Y TRAMADOL HCL. LA COMPOSICION COMPRENDE ADEMAS, EN LA CAPA DE LIBERACION PROLONGADA, HIDROXIPROPILMETILCELULOSA Y RELLENO CON EL FIN DE QUE DICHA CAPA PROLONGADA SE DESHAGA FACILMENTE Y DE MANERA MAS UNIFORME A MEDIDA QUE SE DISUELVE. DICHA COMPOSICION REFIERE A UNA FORMA DE DOSIFICACION DE LIBERACION PROLONGADA UTIL EN EL TRATAMIENTO DE DOLOR CRONICO
PE2011000940A 2008-10-27 2009-10-23 Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol PE20110855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10861808P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
PE20110855A1 true PE20110855A1 (es) 2011-12-05

Family

ID=41514164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000940A PE20110855A1 (es) 2008-10-27 2009-10-23 Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol

Country Status (26)

Country Link
US (1) US20100104638A1 (es)
EP (1) EP2362768B1 (es)
JP (1) JP5713911B2 (es)
KR (3) KR20110119845A (es)
CN (2) CN102264355A (es)
AU (1) AU2009320181B2 (es)
BR (1) BRPI0920082A2 (es)
CA (1) CA2741751C (es)
CL (1) CL2011000935A1 (es)
CO (1) CO6331423A2 (es)
CR (1) CR20110287A (es)
EA (1) EA023149B1 (es)
EC (1) ECSP11011009A (es)
ES (1) ES2582779T3 (es)
HK (1) HK1162915A1 (es)
HN (1) HN2011001184A (es)
IL (1) IL212453A (es)
MX (1) MX339867B (es)
MY (1) MY161550A (es)
NI (1) NI201100079A (es)
NZ (1) NZ592325A (es)
PE (1) PE20110855A1 (es)
TW (1) TWI561257B (es)
UA (1) UA102706C2 (es)
WO (1) WO2010062524A1 (es)
ZA (1) ZA201103880B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
TW201306881A (zh) * 2011-05-06 2013-02-16 Glaxosmithkline Llc 緩釋對乙醯胺基酚調配物
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US20130303632A1 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
IN2013MU03098A (es) * 2013-09-30 2015-07-17 Athena Drug Delivery Solutions Pvt Ltd
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
AU2014365038B2 (en) * 2013-12-16 2019-09-12 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
EP3694557B1 (en) * 2017-10-13 2022-04-13 Altus Formulation Inc. Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206751A (ja) * 1982-05-26 1983-12-02 日石三菱株式会社 創傷被覆材
SG80535A1 (en) 1991-09-06 2001-05-22 Mcneilab Inc Composition comprising a tramadol material and acetaminophen and its use
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1555022B1 (en) 2002-09-21 2008-02-20 Shuyi Zhang Sustained release formulation of acetaminophen and tramadol
KR20050083816A (ko) * 2002-10-25 2005-08-26 라보팜 인코포레이트 24시간 효능의 서방 트라마돌 조성물
US20080176873A1 (en) * 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria
BRPI0612802A2 (pt) * 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
UA94916C2 (ru) * 2005-09-09 2011-06-25 Лабофарм Инк. Композиция тразодона для введения один раз в день
CN1785167A (zh) * 2005-10-08 2006-06-14 王鸣 一种非麻醉性镇痛剂的复方缓释制剂的制备方法
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
MX2010000690A (es) * 2007-07-18 2010-06-25 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8.
CN101969930A (zh) * 2007-12-17 2011-02-09 莱博法姆公司 防滥用控制释放制剂
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic

Also Published As

Publication number Publication date
MX339867B (es) 2016-06-14
CL2011000935A1 (es) 2011-10-21
JP5713911B2 (ja) 2015-05-07
CA2741751C (en) 2017-05-09
CA2741751A1 (en) 2010-06-03
NI201100079A (es) 2011-10-21
TW201028180A (en) 2010-08-01
EP2362768B1 (en) 2016-04-20
US20100104638A1 (en) 2010-04-29
EA023149B1 (ru) 2016-04-29
CN102264355A (zh) 2011-11-30
ECSP11011009A (es) 2011-06-30
JP2012506907A (ja) 2012-03-22
ES2582779T3 (es) 2016-09-15
BRPI0920082A2 (pt) 2019-09-24
MY161550A (en) 2017-04-28
TWI561257B (en) 2016-12-11
WO2010062524A1 (en) 2010-06-03
NZ592325A (en) 2012-09-28
KR20130137720A (ko) 2013-12-17
EA201170616A1 (ru) 2011-12-30
MX2011004403A (es) 2011-05-25
CO6331423A2 (es) 2011-10-20
AU2009320181A1 (en) 2010-06-03
HN2011001184A (es) 2014-09-01
KR20110119845A (ko) 2011-11-02
HK1162915A1 (zh) 2012-09-07
KR20110036858A (ko) 2011-04-11
AU2009320181B2 (en) 2015-08-27
UA102706C2 (ru) 2013-08-12
ZA201103880B (en) 2012-10-31
EP2362768A1 (en) 2011-09-07
KR101631140B1 (ko) 2016-06-20
IL212453A (en) 2017-03-30
CN107028908A (zh) 2017-08-11
CR20110287A (es) 2011-11-10
IL212453A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
PE20110855A1 (es) Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
JP2014507446A5 (es)
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
JP2007527914A5 (es)
PE20081736A1 (es) Compuestos triciclicos, composiciones, y procedimientos
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
WO2009043926A3 (en) Oral fast disintegrating tablets
BRPI0615989B8 (pt) formulação farmacêutica de dosagem oral
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
DK1994926T3 (da) Valsartanformuleringer
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
CL2008000227A1 (es) Composicion farmaceutica que comprende una combinacion de uso oral de tramadol y ketoprofeno; y uso en el tratamiento del dolor.
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
PE20110925A1 (es) Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed